Evidence map›Paper›PMID 30777055›Full record

ArticleBMC cancer2019

Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas.

Anna Ostrovskaya, Caroline Hick, Dana S Hutchinson, Brett W Stringer, Peter J Wookey, Denise Wootten, Patrick M Sexton, Sebastian G B Furness

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Anna OstrovskayaDrug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Caroline HickDrug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Dana S HutchinsonDrug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Brett W StringerQIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Peter J WookeyDepartment of Medicine/Cardiology (Austin Health, Heidelberg), University of Melbourne, Lance Townsend Building, Level 10, Austin Campus, Studley Road, Heidelberg, VIC, 3084, Australia.
Denise WoottenDrug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Patrick M SextonDrug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Sebastian G B FurnessDrug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. sebastian.furness@monash.edu.ORCID http://orcid.org/0000-0001-8655-8221
Monash University · AUFudan University · CNDiscovery Institute · USQIMR Berghofer Medical Research Institute · AUThe University of Melbourne · AU

Funding

National Key Research and Development Program of China 2017YFD0500804National Natural Science Foundation of China 31802222Natural Science Foundation of Jiangsu Province BK20160064
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is the most common and aggressive type of primary brain cancer. With median survival of less than 15 months, identification and validation of new GBM therapeutic targets is of critical importance.

resultsIn this study we tested expression and performed pharmacological characterization of the calcitonin receptor (CTR) as well as other members of the calcitonin family of receptors in high-grade glioma (HGG) cell lines derived from individual patient tumours, cultured in defined conditions. Previous immunohistochemical data demonstrated CTR expression in GBM biopsies and we were able to confirm CALCR (gene encoding CTR) expression. However, as assessed by cAMP accumulation assay, only one of the studied cell lines expressed functional CTR, while the other cell lines have functional CGRP (CLR/RAMP1) receptors. The only CTR-expressing cell line (SB2b) showed modest coupling to the cAMP pathway and no activation of other known CTR signaling pathways, including ERK

conclusionsThis study shows that GPCR signaling can display significant variation depending on cellular system used, and effects seen in model recombinant cell lines or tumour cell lines are not always reproduced in a more physiologically relevant system and vice versa.

Indexed as

AgedAged, 80 and overBrain NeoplasmsCalcitonin Receptor-Like ProteinCell Culture TechniquesCell ProliferationGlioblastomaHumansMiddle AgedMitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesPhosphorylationReceptor Activity-Modifying Protein 1Receptor Activity-Modifying Protein 2Receptors, CalcitoninSignal TransductionCalcitonin Receptor-Like ProteinCALCRL protein, humanMitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesRAMP1 protein, humanRAMP2 protein, humanReceptor Activity-Modifying Protein 1Receptor Activity-Modifying Protein 2Receptors, CalcitoninCalcitonin receptorGlioblastomaGPCRSignaling

Identifiers

PMID30777055
PMCPMC6379965
OpenAlexW2925313395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.